Evidence map›Paper›PMID 34057569›Full record

ArticleAnnals of surgical oncology2021

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of 'Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.'

Luigi Marano, Daniele Marrelli, Paolo Sammartino, Daniele Biacchi, Luigina Graziosi, Elisabetta Marino, Federico Coccolini, Paola Fugazzola, Mario Valle, Orietta Federici and 9 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Role of surgery in metastatic gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Luigi MaranoDepartment of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy. luigi.marano@unisi.it.ORCID http://orcid.org/0000-0002-9777-9588
Daniele MarrelliDepartment of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy.
Paolo SammartinoCytoreductive Surgery and HIPEC Unit, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.
Daniele BiacchiCytoreductive Surgery and HIPEC Unit, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.
Luigina GraziosiGeneral and Emergency Surgery, University of Perugia, Perugia, Italy.
Elisabetta MarinoGeneral and Emergency Surgery, University of Perugia, Perugia, Italy.
Federico CoccoliniGeneral, Emergency and Trauma Surgery Department, Bufalini Hospital, Cesena, Italy.
Paola FugazzolaGeneral, Emergency and Trauma Surgery Department, Bufalini Hospital, Cesena, Italy.
Mario ValleDepartment of Digestive Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Orietta FedericiDepartment of Digestive Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Dario BarattiFondazione IRCCS Istituto Nazionale Dei Tumori di Milano, Peritoneal Surface Malignancies Unit, Milan, Italy.
Marcello DeracoFondazione IRCCS Istituto Nazionale Dei Tumori di Milano, Peritoneal Surface Malignancies Unit, Milan, Italy.
Andrea Di GiorgioSurgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Antonio MacrìPeritoneal Surface Malignancy and Soft Tissue Sarcoma Program, Messina University Medical School Hospital, Messina, Italy.
Enrico Maria PasqualDepartment of Medical Area, University of Udine, Santa Maria della Misericordia University Hospital Udine, Udine, Italy.
Massimo FramariniDepartment of Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
Marco VairaCandiolo Cancer Institute, Unit of Surgical Oncology, FPO-IRCCS, Candiolo, Italy.
Franco RovielloDepartment of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy.
Italian Peritoneal Surface Malignancies Oncoteam (S.I.C.O.)
University of Siena · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale “M. Bufalini” di Cesena · ITSapienza University of Rome · ITUniversity of Perugia · ITAgostino Gemelli University Polyclinic · ITCandiolo Cancer Institute · ITOspedale G.B. Morgagni - L.Pierantoni · ITUniversity of Messina · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of multimodality treatment, including cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC), has led to promising results in selected patients with peritoneal disease of gastric origin. The aim of this study was to investigate the short- and long-term outcomes of CRS/HIPEC in the treatment of synchronous peritoneal metastasis in gastric cancer.

methodsThe Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O. retrospective registry included patients with synchronous peritoneal malignancy from gastric cancer submitted to gastrectomy with CRS and HIPEC between 2005 and 2018 from 11 high-volume, specialized centers.

resultsA total of 91 patients with a median age of 58 years (range 26-75) were enrolled. The median overall survival (OS) time for the whole group of patients was 20.2 months (95% confidence interval [CI] 11.8-28.5] and the median recurrence-free survival (RFS) was 7.3 months (95% CI 4-10.6). The completeness of cytoreduction score (CCS) of 0 and Peritoneal Cancer Index (PCI) score of ≤ 6 groups showed a significantly better long-term survival (median OS 40.7 and 44.3 months, respectively) compared with the incomplete resected groups (median OS 10.7 months, p = 0.003) and PCI score of > 6 group (median OS 13.4 months, p = 0.005). A significant difference was observed in the survival rate according to neoadjuvant treatment (untreated patients: 10.7 months, 95% CI 5.1-16.2; treated patients: 35.3 months, 95% CI 2.8-67.8; p = 0.022).

conclusionsIn referral centers, CRS and HIPEC after neoadjuvant treatment significantly improved survival in selected patients. Patients with a PCI score ≤ 6, complete cytoreduction, negative nodal involvements, and negative cytology had encouraging results, showing a clinically meaningful survival.

Indexed as

Hyperthermia, InducedPeritoneal NeoplasmsStomach NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCytoreduction Surgical ProceduresHumansHyperthermic Intraperitoneal ChemotherapyItalyMiddle AgedRetrospective StudiesSurvival Rate

Identifiers

PMID34057569
PMCPMC8590997
OpenAlexW3164786456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.